The patient died of acute liver failure; the maker of the gene therapy noted that the patient also had a recent ...
Several companies will head to the FDA seeking approval of new Duchenne muscular dystrophy treatments next year but the death of a patient taking Sarepta’s Elevidys raises important safety questions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback